BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30385823)

  • 1. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
    Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
    Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
    Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
    J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
    Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.
    Rieger G; Koelzer VH; Dawson HE; Berger MD; Hädrich M; Inderbitzin D; Lugli A; Zlobec I
    Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer.
    Koelzer VH; Karamitopoulou E; Dawson H; Kondi-Pafiti A; Zlobec I; Lugli A
    Br J Cancer; 2013 May; 108(10):2088-96. PubMed ID: 23632477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.
    Konishi Y; Kawamata F; Nishihara H; Homma S; Kato Y; Tsuda M; Kohsaka S; Einama T; Liu C; Yoshida T; Nagatsu A; Tanino M; Tanaka S; Kawamura H; Kamiyama T; Taketomi A
    Med Oncol; 2018 Jun; 35(7):104. PubMed ID: 29892782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour budding in solid cancers.
    Lugli A; Zlobec I; Berger MD; Kirsch R; Nagtegaal ID
    Nat Rev Clin Oncol; 2021 Feb; 18(2):101-115. PubMed ID: 32901132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
    Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
    Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
    Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
    Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive power of tumour budding for lymph node metastasis in colorectal carcinomas: A retrospective study.
    Deb B; Jacob SE
    Indian J Med Res; 2019 Dec; 150(6):635-639. PubMed ID: 32048628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.